Zongliang Lu
- Biotechnology top 2%
- Microbial Metabolism and Applications 6
- Pharmacology top 2%
-
- Traditional Chinese Medicine Studies 3
- Pharmacology top 10%
-
- Lipoproteins and Cardiovascular Health 9
-
- Lipid metabolism and disorders 7
-
- Nutrition and Health in Aging 3
-
- Atherosclerosis and Cardiovascular Diseases 3
-
- Medicinal Plants and Bioactive Compounds 2
-
- Tea Polyphenols and Effects 2
Zongliang Lu
19 papers receiving 542 citations
Peers
Comparison fields: 5 of 64
- Biotechnology 306
- Pharmacology 198
- Complementary and alternative medicine 90
- Biochemistry 38
- Pharmacology 92
Countries citing papers authored by Zongliang Lu
This map shows the geographic impact of Zongliang Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zongliang Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zongliang Lu more than expected).
Fields of papers citing papers by Zongliang Lu
This network shows the impact of papers produced by Zongliang Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zongliang Lu. The network helps show where Zongliang Lu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Zongliang Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2024 | 4 | |
| 3 | 2024 | 0 | |
| 4 | 2010 | 35 | |
| 5 | 2010 | 17 | |
| 6 | 2009 | 45 | |
| 7 | 2008 | 236 | |
| 8 | 2007 | 29 | |
| 9 | 2007 | 34 | |
| 10 | 2006 | 12 | |
| 11 | A Commentary on the Chinese Coronary Secondary Prevention Study | 2006 | 1 |
| 12 | [China coronary secondary prevention study: analysis of patients with different myocardial infarction history]. | 2006 | 3 |
| 13 | 2006 | 6 | |
| 14 | [The beneficial effects of lipid-lowering therapy with xuezhikang on cardiac events and total mortality in coronary heart disease patients with or without hypertension: a random, double-blinded, placebo controlled clinical trial]. | 2006 | 2 |
| 15 | [Apolipoprotein B is associated with metabolic syndrome in Chinese pedigrees with familial hyperlipidemia]. | 2005 | 3 |
| 16 | [China coronary secondary prevention study (CCSPS): outcomes from analysis of coronary heart disease patients with diabetes]. | 2005 | 5 |
| 17 | [China coronary secondary prevention study (CCSPS)]. | 2005 | 10 |
| 18 | 1997 | 112 | |
| 19 | 1996 | 2 | |
| 20 | 1996 | 19 |
About Zongliang Lu
Zongliang Lu is a scholar working on Biotechnology, Complementary and alternative medicine and Cardiology and Cardiovascular Medicine, having authored 20 papers that have together received 577 indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (9 papers), Lipid metabolism and disorders (7 papers), Microbial Metabolism and Applications (6 papers), Nutrition and Health in Aging (3 papers), Atherosclerosis and Cardiovascular Diseases (3 papers), Traditional Chinese Medicine Studies (3 papers), Medicinal Plants and Bioactive Compounds (2 papers) and Tea Polyphenols and Effects (2 papers). The work is most often cited by research in Biotechnology (306 citations), Pharmacology (198 citations) and Complementary and alternative medicine (90 citations). Zongliang Lu has collaborated with scholars based in China, United Kingdom and United States. Frequent co-authors include Yangfeng Wu, Shui‐Ping Zhao, Osvaldo Brusco, John Morgan, David M. Capuzzi, Zuo Chen, Xue-hai Yu, Jian‐Jun Li, Jun‐Xian Wang and Jia‐Shi Zhu. Their work appears in journals such as The American Journal of Cardiology, Journal of the American Geriatrics Society and Nutrition.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.